WallStSmart

The Ensign Group Inc (ENSG)vsOncology Institute Inc (TOI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 1092% more annual revenue ($5.06B vs $424.38M). ENSG leads profitability with a 6.8% profit margin vs -15.5%. ENSG earns a higher WallStSmart Score of 57/100 (C).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

TOI

Hold

42

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: 0.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Intrinsic value data unavailable for TOI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

TOI2 strengths · Avg: 9.0/10
Debt/EquityHealth
-2.2310/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
21.5%8/10

Revenue surging 21.5% year-over-year

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

TOI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.00M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : TOI

The strongest argument for TOI centers on Debt/Equity, Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : TOI

The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ENSG carries more volatility with a beta of 0.80 — expect wider price swings.

TOI is growing revenue faster at 21.5% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSG scores higher overall (57/100 vs 42/100) and 20.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Oncology Institute Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Oncology Institute Inc (ticker: TOI) is a leading healthcare organization committed to revolutionizing cancer care through its expansive network of specialized clinics and advanced treatment options. Focused on improving patient outcomes, the company utilizes cutting-edge technologies and tailored treatment strategies, while actively engaging in clinical trials and partnerships with esteemed research institutions. As the demand for innovative cancer therapies accelerates, TOI is well-positioned to capitalize on its extensive pipeline and deep oncology expertise, solidifying its role as a vital participant in the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?